Please login to the form below

Not currently logged in
Email:
Password:

Lilly extends contract with Chinese CRO ShangPharma

Shanghai-based firm has opened a new facility to meet the pharma company's growing needs

Lilly has signed a multi-year extension of its contract with Shanghai-based research and development outsourcing company ShangPharma.

The pharma company is ShangPharma's largest customer, accounting for 21 per cent of its 2010 revenue, and the CRO has opened a new facility just to meet Lilly's growing needs.

William Dai, ShangPharma's chief financial officer, said: "The opening of this state of the art facility gives us the capacity to expand our operations and better meet Lilly's growing demand. We expect to achieve high utilisation of the new facility from day one."

The new facility adds 110,000 square feet of laboratory and office space to the company's overall capacity and will be fully dedicated to supporting Lilly's ongoing and future projects.

"We are delighted to extend and deepen our highly productive relationship with Lilly," said Michael Xin Hui, founder and CEO of ShangPharma.

"Renewing our agreement to serve as a key support partner for Lilly's discovery services is a clear indication that international pharmaceutical companies appreciate the high quality of ShangPharma's team and the excellence of our R&D capability.

“Our focus on building trust with companies through years of cooperation helps ShangPharma better understand our customers' needs and exceed their expectations."

China's pharmaceutical market climbed in value from $36.6bn in 2008 to $46bn in 2010 and companies are increasingly looking to align themselves with it.

Last month Merck & Co joined the ranks of pharma companies setting up R&D locations in China, signally its intention to set up a drug discovery and development facility in Beijing as part of a $1.5bn investment programme.

2011 also saw a number of manufacturing investments in the country, with AstraZeneca and Boehringer Ingelheim both planning new or expanded facilities.

11th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics